 |
 |
 |
 |
 |
 |
 |
||||
|
||||||||||
 Construction, Characterization and PathologyPolypeptide Growth Factors and Prostate CancerAndrogen Axis and Prostate CancerImmunotherapyPre-Clinical TrialsReviews |
1. Gingrich, J.R., Barrios, R.J. Kattan, M.W., Nahm, H.S., Finegold, M.J. and Greenberg, N.M. 1997. Androgen independent prostate cancer progression in the TRAMP model. Cancer Research 57:4687-4691. 2. Eng, M.H., Charles, L.G., Ross, B.D., Chrisp, C.E., Pienta, K.J., Greenberg, N.M., Hsu, C.X. and Sanda, M.G. 1999. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 54: 1112-1119. 3. Han, G., Foster, B.A., Mistry, S., Buchanan, G., Harris, J.M., Tilley, W.D. and Greenberg, NM. 2001. Hormone status selects for spontaneous androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J. Biol. Chem 276: 11204-11213. [PDF] 4. Buchanan, G., Yang, M., Nahm, H.S., Han, G., Bentel, J.M., Matusik, R.J., Horsfall, D., Marshall. V.R., Greenberg, N.M. and Tilley, W.D. 2001. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol. 15:46-56. [PDF] 5. Buchanan, G., Greenberg, N.M., Scher, H.I., Harris, J.M., Marshall, V.R. and Tilley, W.D. 2001. Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 7: 1273-1281. [PDF] |
